Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 5, 2003, Pages 211-218

  Wójcicki, Jerzy ^a   Jaroszynska, Maria ^a   Droździk, Marek ^a   Pawlik, Andrzej ^a   Gawrónska Szklarz, Barbara ^a   Sterna, Rozalia ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Atenolol; Hyperlipidaemia; Obesity; Pharmacodynamics; Pharmacokinetics; Propranolol

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SOLUBILITY; FEMALE; HEART RATE; HUMAN; HYDROPHILICITY; HYPERLIPIDEMIA; LEAN BODY WEIGHT; LIPOPHILICITY; MALE; OBESITY; PHARMACODYNAMICS; RECORDING; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; ATENOLOL; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HEART RATE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; PROPRANOLOL;

EID: 0042665425     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.357     Document Type: Article

References (19)

1. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997; 53: 238-252.
2. Darrell R, Greenblatt AD. Pharmacokinetics of drugs in obesity. Clin Pharmacokin 1982: 7: 108-124.
3. Darrell R, Greenblatt AD, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981; 217: 681-685.
4. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985; 26: 133-139.
5. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107.
6. Duane WC. Cholesterol metabolism in familial hypertriglyceridemia: Effects of obesity versus triglyceride level. J Lab Clin Med 1997; 130: 635-642.
7. Wójcicki J, Sulyc-Bielicka V, Kutrzeba J, Gawronska-Szklarz B, Drozdzik M, Sterna R. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J Clin Pharmacol 1999; 39: 826-833.
8. Cheymol G. Clinical pharmacokinetics of drug in obesity: an update. Clin Pharmacokin 1993; 25: 103-114.
9. Gengo FM, Huntoon L, Wiliam B, McHugh C. Lipid-soluble and water-soluble β-blockers. Arch Intern Med 1987; 47: 39-43.
10. Ochs HR, Greenblatt DJ, Arendt RM, Schäfer-Korting, Mutschler E. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity. Arzneimittilforsch 1985; 35: 1580-1582.
11. Galletti F, Fasano ML, Ferrara LA, Groppi A, Montagna M, Mancini M. Obesity and beta-blockers: Influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol 1989; 29: 212-216.
12. Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997; 51: 493-498.
13. Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997; 43: 563-570.
14. Wojcicki J, Sterna R, Sulzyc-Bielicka V, Gawronska-Szklarz B, Drozdzik M, Musial HD. Effects of hypolipemic therapy on the pharmacokinetics of propranolol. Curr Ther Res 1999; 60: 20-30.
15. Hermansson J. Simultaneous determination of D- and L-propranolol in human plasma by high performance liquid chromatography. J Chromatogr Biomed Appl 1980; 221: 109-117.
16. Poirier JM, Le Jeune C, Cheymol G, Cohen A, Barre J. Comparison of propranolol and sotalol pharmacokinetics in obese subjects. J Pharm Pharmacol 1990; 42: 344-348.
17. Womersley J, Durning JV, Boddy K, Mahaffy M. Influence of muscular development, obesity and age on the fat - free mass of adults. J Appl Physiol 1976; 47: 223-229.
18. Forbes GB, Weile SL. Lean body mass in obesity. Int J Obesity 1983; 7: 99-107.
19. Bickel MH. Factors affecting the storage of drugs and other xenobiotics in adipose tissue. In Advances in Drug Research, Vol. 25, Testa B, Meyer UA (eds). Academic Press: London, 1994; 55-86.